Interview with Leigh Berryman , Chief Executive Officer, Maccine
Which previous professional experiences have led you to join Maccine? Getting my own company to go public in 2006 in Canada was a success for me; the company had grown…
Address: 10 Science Park Road 01-05 The Alpha Singapore Science Park II Singapore 117684,Singapore
Tel: +65 6622 9540
Web: http://www.maccine.com/index.php
Maccine is an established preclinical contract research organization providing innovative discovery support and regulatory safety assessment services.
Operating on a collaborative partnering model, Maccine has developed a portfolio of in vivo assays in key therapeutic areas including Neurology, Psychiatry, Metabolic Disorders, Pain & Inflammation, Oncology, Musculoskeletal Disorders and Women’s Health.
Naturalistic models, clinical biomarkers and clinical technology platforms are employed to better represent the clinical disease state. The team is supported by significant investment in high-end technology and access to a world class scientific community.
Preclinical Contract Research
Which previous professional experiences have led you to join Maccine? Getting my own company to go public in 2006 in Canada was a success for me; the company had grown…
Charles Stacey, President and CEO of Cerecin, discusses the company’s strategic direction and partnerships as it advances its Alzheimer’s treatment into Phase 3 trials. He highlights the importance of collaboration…
Thanks to its strategic location and pro-business environment, Singapore has established itself as a major pharma manufacturing hub in the Asia-Pacific region. Five Big Pharma companies have stepped up their…
Writing in the November 2024 edition of DIA’s Global Forum magazine, Johnson & Johnson’s Sandy Chan looks at the fast-evolving regulatory framework for medicines in the dynamic Asia-Pacific region. …
A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest…
A roundup of some of the most important recent pharma news from the dynamic ASEAN region, including a big new investment from Novartis in its antibody plant in Singapore, the…
The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local…
As the COVID-19 pandemic showed, vaccination is perhaps the most important tool a country has in maintaining the health of its population. Writing in the May 2023 edition of DIA’s…
The latest pharma and healthcare news from Southeast Asia, including the partnership between KPJ Healthcare and Samsung; Specialised Therapeutics’ immuno-oncology therapy; Singapore biotech CytoMed Therapeutics’ IPO, the Malaysian approval of…
The latest pharma and healthcare news from Southeast Asia, including the proposed healthcare programs of Thailand’s political parties for the upcoming election; Singapore’s approval of Pfizer’s 20-valent pneumococcal conjugate vaccine;…
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
MSD is set to inject an additional USD 500 million into its existing Singapore manufacturing operations with two new facilities to produce vaccines and biologics. One of the new plants…
On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach…
See our Cookie Privacy Policy Here
